Zhilin Hou

A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy

K. Liby, Di Zhang, A. Odom, 2021, Molecular Cancer Therapeutics.

Exploring structural effects in a new class of NRF2 inhibitors.

K. Gallo, K. Liby, A. Odom, 2023, RSC medicinal chemistry.

Synthesis, structure, properties, and cytotoxicity of a (quinoline)RuCp+ complex.

J. Tepe, A. Odom, Allison Vanecek, 2022, Dalton transactions.